Research use only (RUO): Qualified laboratory research only — not for human or veterinary use. Statement

Free shipping on orders over $200

HALO
Cart0

Research comparison

Tirzepatide vs Retatrutide

Tirzepatide and Retatrutide are the dual- and triple-agonist endpoints of the incretin research spectrum. Both engage GLP-1R and GIPR; only Retatrutide adds the glucagon receptor (GCGR). The comparison isolates the single most-studied open question in incretin pharmacology — what does GCGR co-agonism contribute on top of dual GLP-1R/GIPR activation?

By · Reviewed · Editorial standards

Short answer

Tirzepatide and Retatrutide are the dual- and triple-agonist endpoints of the incretin research spectrum. Both engage GLP-1R and GIPR; only Retatrutide adds the glucagon receptor (GCGR). The comparison isolates the single most-studied open question in incretin pharmacology — what does GCGR co-agonism contribute on top of dual GLP-1R/GIPR activation?

Research-context summary: If the research question is “what does GIPR add to GLP-1R?” — Tirzepatide. If it is “what does glucagon co-agonism add on top of GLP-1R/GIPR?” — Retatrutide, run alongside Tirzepatide as the dual-agonist reference. For thermogenesis and energy-expenditure endpoints, Retatrutide’s GCGR arm is the differentiator.

Use limitation: HALO comparison pages are for research context only; both materials are RUO and not for human or veterinary use.

TirzepatideRetatrutide
Receptor profileGLP-1R partial + GIPR full (dual)GLP-1R + GIPR + GCGR (triple, full at all three)
Class / identityGIP(1-39) backbone with GLP-1-mimicking residues; C18 diacid at K2039-aa tri-agonist scaffold (LY3437943); albumin-binding fatty diacid
Molecular weight≈ 4,813.5 g/mol≈ 4,731 g/mol
GCGR signallingNoneFull — hepatic glucose output + BAT thermogenesis (UCP-1)
GLP-1R characterPartial agonist (reduced β-arrestin recruitment)Full agonist
Half-life (research models)~120 h (high albumin affinity)Multi-day (~6 days); supports once-weekly research dosing
Primary research leverIncremental value of GIPR co-agonism over GLP-1R aloneIncremental value of GCGR thermogenesis over GLP-1R/GIPR dual
Thermogenesis armIndirect / GIPR-modulatedDirect — GCGR-driven brown-adipose-tissue activation

Dual versus triple — the GCGR question

Tirzepatide is a dual GLP-1R / GIPR co-agonist on a GIP(1-39) backbone, acting as a partial (β-arrestin-attenuated) agonist at GLP-1R and a full agonist at GIPR. Retatrutide (LY3437943) is a triple agonist that adds full glucagon-receptor (GCGR) activation to the same two incretin receptors. Because the two compounds share the GLP-1R/GIPR foundation, running them side by side is the cleanest available way to attribute an outcome specifically to the glucagon arm.

What GCGR adds beyond dual agonism

The differentiating mechanism is glucagon-receptor activation. GCGR engagement on brown adipose tissue drives sympathetically-mediated thermogenesis and UCP-1 upregulation, increasing energy expenditure in preclinical models — an effect Tirzepatide cannot produce. In tri-agonist research the glucagon signal is glycaemically buffered: co-activated GLP-1R suppresses alpha-cell glucagon secretion and amplifies glucose-dependent insulin release, so the thermogenic and lipolytic effects of GCGR proceed without the hyperglycaemia native glucagon would cause. BAT glucose-uptake imaging studies have shown greater uptake with triple-agonist treatment than with matched-dose dual agonists, supporting GCGR as the primary mediator of the thermogenic increment.

The GLP-1R character difference

A subtler distinction: Tirzepatide is a partial GLP-1R agonist with reduced β-arrestin recruitment, whereas Retatrutide is a full GLP-1R agonist. For research dissecting receptor desensitisation, biased agonism, or endosomal signalling at GLP-1R, this difference matters and should be controlled for when interpreting outcomes attributed to the glucagon arm.

Identity and handling

Both ship lyophilized at ≥98% HPLC purity with independent COA and are strongly albumin-binding — serum-containing assay media may sequester free compound. Both reconstitute in PBS pH 7.4 (cell culture) or sterile bacteriostatic water (in-vivo work) and store −20 °C dry, 4 °C reconstituted ≤28 days. Both are offered in large vial sizes (up to 100 mg) to support the chronic multi-week dosing and receptor-antagonist dissection protocols typical of multi-receptor metabolic research.

Common comparison questions

What is the difference between Tirzepatide and Retatrutide?
Both activate GLP-1R and GIPR. Retatrutide adds full glucagon-receptor (GCGR) activation, making it a triple agonist. Tirzepatide is a dual agonist. The comparison isolates what the glucagon arm contributes on top of dual incretin agonism.
Why is Retatrutide associated with greater thermogenesis than Tirzepatide?
Its GCGR arm activates brown adipose tissue via sympathetic stimulation and UCP-1 upregulation, raising energy expenditure. Tirzepatide lacks GCGR engagement, so it cannot reproduce this direct thermogenic pathway.
Are the two compounds used together in research?
Yes. Because they share the GLP-1R/GIPR foundation, running Tirzepatide (dual) against Retatrutide (triple) on the same model is the canonical design for attributing a metabolic outcome specifically to glucagon-receptor co-agonism.
Do they differ at GLP-1R itself?
Yes — Tirzepatide is a partial GLP-1R agonist with reduced β-arrestin recruitment, while Retatrutide is a full GLP-1R agonist. This should be controlled for when interpreting outcomes attributed to the glucagon arm.

Research use only. Both compounds are sold by HALO for in vitro and qualified laboratory research only. Not for human or veterinary use, diagnosis, or treatment.